Phenotypic heterogeneity in cancer is often caused by different patterns of genetic alterations. Understanding such phenotype-genotype relationships is fundamental for the advance of personalized medicine. One of the important challenges in the area is to predict drug response on a personalized level. The pathway-centric view of cancer significantly advanced the understanding of genotype-phenotype relationships. However, most of network identification methods in cancer focus on identifying subnetworks that include general cancer drivers or are associated with discrete features such as cancer subtypes, hence cannot be applied directly for the analysis of continuous features like drug response. On the other hand, existing genome wide association approaches do not fully utilize the complex proprieties of cancer mutational landscape. To address these challenges, we propose a computational method, named NETPHIX (NETwork-to-PHenotpe assocIation with eXlusivity), which aims to identify mutated subnetworks that are associated with drug response (or any continuous cancer phenotype). Utilizing properties such as mutual exclusivity and interactions among genes, we formulate the problem as an integer linear program and solve it optimally to obtain a set of genes satisfying the constraints. NETPHIX identified gene modules significantly associated with many drugs, including interesting response modules to MEK1/2 inhibitors in both directions (increased and decreased sensitivity to the drug) that the previous method, which does not utilize network information, failed to identify. The genes in the modules belong to MAPK/ERK signaling pathway, which is the targeted pathway of the drug.
Introduction
Genetic alterations in cancer are associated with diverse phenotypic properties such as drug response or patient survival. However, the identification of mutations causing specific phenotypes and the interpretation of the phenotype-genotype relationships remain challenging due to a large number of passenger mutations and cancer heterogeneity. Indeed, the relationships between genotype and phenotype in most tumors are complex and different mutations in functionally related genes can lead to the same phenotype. The pathway-centric view of cancer [1, 2, 3] suggests that cancer phenotypes should be considered from the context of dysregulated pathways rather than from the perspective of mutations in individual genes. Such pathway-centric view significantly advanced the understanding of the mechanisms of tumorigenesis. Many computational methods to identify cancer driving mutations have been developed based on pathway approaches [4, 5, 6, 7, 8, 9] . Network based approaches have been further applied to find subnetworks associated with various disease phenotypes [4, 6, 10, 11, 12] .
Those methods have been developed aiming to find genes whose mutations are associated specifically with given phenotypes rather than finding general cancer drivers. Recent projects have characterized drug sensitivity for a large number of drugs in hundreds of cancer cell lines [13] , [14] . This data, together with information about the genetic alterations in these cells, can be used to understand how genomic alterations impact drug sensitivity. While the success of network based methods in other cancer domains suggests that such approaches should be also useful in the studies of drug response, most of previous approaches focused on discrete phenotypic traitse.g., cancer vs. healthy, good or bad prognosis, or cancer subtypes -and therefore, cannot be directly applied to the analysis of continuous features such as drug sensitivity. Several algorithms for the identification of mutations associated with drug response have been previously developed [15, 16] but without considering functional relationships among genes. For example, REVEALER used a re-scaled mutual information metric to iteratively identify a set of genes associated with the phenotype [16] . UNCOVER employs an integer linear programming formulation based on the set cover problem, by designing the objective function to maximize the association with the phenotype and preferentially select mutually exclusive gene sets [15] . However, without interaction information, the genes identified by the algorithms may not belong to the same pathways, making them more likely to include false positives and making it difficult to interpret the uncovered association and the underlying mechanism.
To address these challenges, we introduce a computational tool named NETPHIX (NETwork-toPHenotype assocIation with eXlusivity). With the goal of identifying mutated subnetworks that are associated with a continuous phenotype, we formulate the problem as an integer linear program and solve it to optimality using CPLEX. For each drug, we attempt to identify both directions of associated subnetworks-a subnetwork whose alterations correlate with increased sensitivity to the drug (decreased cell survival) and a subnetwork that correlates with reduced sensitivity to the drug (increased cell survival). Based on the fact that mutations in cancer drivers tend to be heterogeneous, our algorithm builds on combinatorial optimization techniques involving set cover and network constraints. In addition, NETPHIX preferentially selects mutually exclusive genes as the solution, utilizing an observation that patient groups harboring different cancer driving mutations tend to be mutually exclusive [17, 18, 19, 7, 20, 21] . This approach together with a carefully designed strategy for selecting subnetwork size allows to leave out passenger mutations from the sensitivity networks. There have been related studies combining GWAS analysis with network constraints [22, 23, 24, 25] . While these methods generally perform well at pointing broadly defined disease related functional pathways, they do not consider complex properties of cancer mutations such as the aforementioned mutual exclusivity of cancer drivers, and are not designed to zoom on subnetworks that are specific enough to help understand drug action. As discussed later in this work, the genomic landscape related to drug response can be complex and mutations in different genes in the same pathway can affect the response differently. Pharmaceutical drugs are often developed to target specific genes, and the response depends on the function and the mutation status of the gene as well as other genes in the same pathway. We evaluated NETPHIX and other related methods using simulations and showed that NETPHIX outperforms competing methods. Applying NETPHIX to drug response data, we identified sensitivityassociated (increasing or decreasing the sensitivity) subnetworks for a large set of drugs. These subnetworks provided important insights into drug action. Effective computational methods to discover these associations will improve our understanding of the molecular mechanism of drug sensitivity, help to identify potential dug combinations, and have a profound impact on genome-driven, personalized drug therapy. NETPHIX is available at https://www.ncbi.nlm.nih.gov/CBBresearch/ Przytycka/index.cgi#netphlix 2 Method
The NETPHIX method overview
Given gene alteration information of cancer samples and their drug sensitivity profiles (or any cancerrelated, continuous phenotypes), NETPHIX aims to identify genetic alterations underlying the phenotype of interest. Starting with the assumption that genes whose mutations lead to the same phenotype must be functionally related, NETPHIX utilizes functional interaction information among genes and enforces the identified genes to be highly connected in the network while, at the same time, making sure that the aggregated alterations of these genes are significantly associated with the given phenotype ( Figure 1a ). In addition, to leverage the property of heterogeneity and mutual exclusivity, NETPHIX utilizes a set cover approach and penalizes overlapping mutations. Specifically, it has been observed that patient groups harboring different cancer driving mutations tend to be mutually exclusive. This property may arise when mutations in two different genes lead to dysregulation of the same cancer driving pathway and the role of the two genes for cancer progression is redundant. In such cases, observing mutations in both genes in one patient is unlikely. Building on this observation, NETPHIX identifies a connected set of genes S such that the sum of phenotypic weights of the patients with alterations in S (minus the penalties for overlapping alterations) is maximized. For example, in Figure 1a , the combined alteration of gene set A, B, C would be identified by NETPHIX as the module is functionally connected and has significant positive association with the phenotype (even though individual gene associations may not be as significant). The patients with alterations in genes A and B are completely mutually exclusive while there is only one patient with overlapping mutations in B and C. We formulated the problem as an integer linear program (ILP) and solved it to obtain the optimal set of genes that satisfies the constraints using CPLEX (https://www.ibm.com/analytics/ cplex-optimizer). We provide the formal definition of the problem and the detailed ILP formu-lation in Section 2.2 and 2.3, respectively. Once we obtain the optimal gene modules, we assess both the significance and robustness of the identified modules by performing permutation tests and bootstrapping (Figure 1b and Section 4.2). To assess the significance of the association between the phenotype and the identified subnetwork, we performed permutation tests by permuting the phenotype profile of the patients. Note that our algorithm is designed to identify the modules associated specifically with a given phenotype (e.g., drug sensitivity to each drug) rather than finding general cancer drivers, and the permutation test will estimate the significance of the association of the given phenotype profile compared with randomly generated phenotypes. In addition, we performed another permutation test based on permutations of functional interactions (in a degree preserving way), which assess the importance of the interaction information in the solution. Finally, we also examine the robustness of the gene selections by performing bootstrap sampling of the patients and solved the ILP with the phenotype and alterations profiles for the sampled sets of patients. See Section 4.2 for the details of the permutation and bootstrapping procedures.
Formal definition of the computational problem
We are given a graph G = (V, E), with vertices V = {1, . . . , n} representing genes and edges E representing interactions among genes. Let P denote the set of m patients (samples). For each sample j ∈ P , we are also given a phenotype profile value w j ∈ R which quantitatively measures a phenotype (e.g., drug response, pathway activation, etc.). Let P i ⊆ P be the set of samples in which gene i ∈ V is altered. We say that a patient j ∈ P is covered by gene i ∈ V if j ∈ P i i.e. if gene i is mutated in sample j. We say that a sample j ∈ P is covered by a subset of vertices S ⊆ V , if there exists at least one vertex v in S such that j ∈ P v . Our goal is to identify a connected subgraph S of G of at most k vertices such that the sum of the weights of the samples covered by S is maximized. Since we are interested in functionally complementary mutations, we also penalize coverage overlap when an element is covered more than once by S by assigning a penalty p j for each of the additional times sample j is covered by S. As penalty we use the average of the positive phenotype values if the original value of the element was positive. If the original value of the element was negative we assign a penalty equal to its value. Let c S (j) be the number of times element j ∈ P is covered by S. For a set S of genes, we define its weight W (S) as:
Thus, we define the optimization problem as follows:
The Phenotype Associated Connected Coverage problem: Given a graph G defined on a set of n vertices V , a set P , a family of subsets P = {P 1 , . . . , P n } where for each i, P i ⊆ P is associated with i ∈ V , weights w j and penalties p j ≥ 0 for each sample j ∈ P find the subset S ⊆ V of ≤ k vertices maximizing W (S). The Phenotype Associated Connected Coverage problem is NP-hard since for a complete graph the problem is equivalent to the NP-hard Target Associated k-Set problem studied in [15] . Although the problem is NP-hard, we formulated it as an integer linear programming as described in the next subsection, and solved it to optimality using CPLEX, which can be run in a reasonable amount of time (See Figure S3b for running times for different k's).
ILP formulation
An ILP formulation for Target Associated k-Set problem was considered in [15] . In NETPHIX we include an additional set of constraints that ensures the genes selected in the solution are connected in the network V . Let x i be a binary variable (denoted with x i ∈ B) equal to 1 if gene i ∈ V is selected and x i = 0 otherwise. Let z j be a binary variable equal to 1 if sample j is covered and z j = 0 otherwise. Let y j denote the number of times sample j is covered in the solution. Finally, let w j be the weight of sample j and p j be the penalty for sample j. Our ILP formulation is as follows:
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Constraint (2) impose that the total number of sets in the solution is at most k. Constraints (3) define how many times each sample has been covered. Constraints (4) ensure that for each element j ∈ P , if j is covered by the current solution then the number of times j is covered in the solution is at least 1. Constraints (5) impose that for each element j ∈ P , if j is covered by at least one element in the current solution then j is covered. Constraints (6) were used to ensure the high connectivity of selected module. Specifically, the constraints enforce that each selected gene is connected with at least D fraction of genes in the selected module (other than the gene itself). Note that if D ≥ 0.5, the module is a connected subgraph since for any two non-adjacent vertices, they must have a common neighbor (D = 0.5 is used in our analysis).
In our study, we used a functional interaction network (from STRING database), which is relatively dense. For sparse networks where highly connected components are rare, we may use an alternative approach based on a branch-and-cut algorithm to ensure the connectivity. See Supplementary Section S1 for the description of an alternative algorithm.
To select an appropriate module size k, we computed modules of increasing sizes, stopping the process if increasing module size does not satisfy the constraints on the objective value of the optimal solution and p-values (See Section 4.2 for details).
Results

Evaluation on simulated data
We generated a set of simulated instances where we planted phenotype associated modules with varying parameters onto the background of real cancer cell mutation data (Section 4.1). We then compared the performance of and two related methods -UNCOVER and SigMOD. UNCOVER [15] was proposed previously as a method to identify a set of phenotype-associated genes by considering a similar objective function but without utilizing interaction information. SigMOD is a recently proposed module identification algorithm combining GWAS and network based approach, and it was found to outperform other related methods [25] . SigMOD requires individual association scores of genes to a phenotype as an input, for which we used the p-value of the association of each gene to a phenotype by performing t-tests on the coefficients of univariate linear regression. We planted modules of size 3, 4, and 5 and we evaluated the accuracy of the three methods in identifying the planted modules ( Figure 2 ). For NETPHIX and UNCOVER, we ran the algorithm for different k's, while SigMOD automatically adjust all its parameters to find the best module. All the algorithms uncovered the planted modules in almost all instances ( Figure S1 ). However, only NETPHIX shows very low rate of false positives, i.e., falsely identified genes ( Figure 2 ). NETPHIX usually does not extend the best module with spurious genes even if we searched for modules bigger than planted while UNCOVER tends to add more genes when increasing k. SigMOD identified a large number of spurious genes along the planted modules (approx. 100-180 genes) that are not associated with phenotypes.
Comparison of NETPHIX and UNCOVER on drug response dataset
We applied NETPHIX and UNCOVER to analyze a dataset of 736 cancer cell lines for which somatic alterations and drug sensitivity data for 265 drug sensitivity experiments are available (Section 4.1) and we compared the identified modules ( Figure 3a) . For each drug, we ran both algorithms to identify modules with decreased or increased sensitivity (530 instances in total). For comparison, we considered here modules of size k = 3 and the p-value from the phenotype permutation test p ph ≤ 0.05. NETPHIX reports 182 modules (out of 530 instances) while UNCOVER finds 156 modules. Although our goal is not to identify cancer drivers but to find the genes associated with sensitivity to each drug, cancer drivers are expected to be most relevant to drug response. The modules reported by included a much higher fraction of cancer genes among the genes in the modules as a whole than the UNCOVER modules, and have a much more significant p-value for the enrichment of cancer driving genes (p < 10 −24 , cancer driver genes reported in [3] relevant genes with a higher degree of functional coherence with the drug targets than the UNCOVER modules ( Figure 3a ). In addition to the phenotype permutation test, we performed the network permutation test for NET-PHIX and considered the modules with both p-values p ph ≤ 0.05 and p net ≤ 0.05. NETPHIX identifies 15 modules with decreased sensitivity to drug response (increased cell survival) and 18 modules with increased sensitivity to drug response (decreased cell survival). The genes in the NETPHIX modules as a whole are significantly enriched in well-known cancer genes (p < 10 −16 by Fisher exact test; 27 fold enrichment), showing that NETPHIX identifies modules of genes relevant to the disease (Figure 3a) . Of the 33 instances (phenotype and increased/decreased sensitivity association) for which NETPHIX identifies a module, 15 have no module identified by UNCOVER (p ph ≤ 0.05). Of the remaining 18 instances, in 7 cases the same module is identified by NETPHIX and by UNCOVER, while in 11 cases NETPHIX and UNCOVER report completely or partially different modules ( Figure  3b ). For the latter, to compare the quality of the modules we checked whether the genes in the module and the drug target (that is unknown to the methods) are part of the same pathway, since one can expect that alterations in different members of the molecular mechanism targeted by the drug have a similar effect on drug response. In 10 cases out of 11, the NETPHIX solution has more members in a pathway (by KEGG or Reactome) that includes the drug target than UNCOVER solutions, while in the remaining case the solutions from the two algorithms have the same number of members in such pathways. Note that since NETPHIX has additional network constraints compared to UNCOVER, the values of the objective function for NETPHIX's modules cannot be greater than those of UNCOVER for the same instances. Nonetheless, we found that the objective values of NETPHIX's modules are close to the ones of UNCOVER (i.e., at least 75% of UNCOVER's values for most instances, Figure S3 ) while obtaining more functionally coherent modules.
Biological implications of drug sensitivity modules identified by NETPHIX
Application of NETPHIX to 530 instances of drug response profiles (increased and decreased sensitivity for 265 drug experiments) with different module sizes k's resulted in 166 modules that are significantly associated with drug sensitivity (Table S2) . See Section 4.2 for detailed description on how significant modules are selected. Many of the modules identified by NETPHIX provide interesting insights related to drug action. In particular, we analyzed the response to drugs targeting the RAS/MAPK pathway (Table S1 ure 4e). This pathway regulates the growth, proliferation and apoptosis and is often dysregulated in various cancers. Among the most common mutations of this pathway are mutations of BRAF. Interestingly, NETPHIX identified the same module (BRAF, KRAS, and NRAS) as associated with increased sensitivity to several of those drugs (CI-1040, PD032590, and Refametinib). All these three drugs act by blocking MEK1 and MEK2 genes that are immediately downstream of BRAF/KRAS/NRAS and thus increased sensitivity of this subnetwork is consistent with the action of these drugs. Moreover, NETPHIX identified the module of genes ERBB2 (amplification), MYC, and RB1 (mutations) as associated with decreased sensitivity to these three drugs. Selumetinib (another drug targeting MEK 1/2) and VX-11e (which blocks ERK2 gene that is downstream of MEK 1/2) have similar response (Figures 4a,b and S4, and Tables S1 and S2 ). All the genes in the modules are related to the MAPK/ERK signaling pathway; BRAF, KRAS, NRAS are three core members, ERBB2 is a receptor protein that, in particular, signals through this pathway, while MYC and RB1 are downstream of the MAPK/ERK signaling pathway. These findings indicate that the alterations in different components of the same pathway can contribute to drug sensitivity in different ways.
In contrast to the response to MEK1/2 and ERK2 inhibitors, the drugs directly targeting BRAF are associated with more heterogeneous subnetworks (Table S1 ), which suggests that patient specific mutational profile can provide important clues in predicting drug response. The drugs associated with similar modules but with opposite response can be candidates for combination drug therapy. For example, we identified Afatinib as having a subnetwork of EGFR, ERBB2, FOXP3 with increased sensitivity. This suggest that it might be beneficial to use Afatinib in combination with MEK 1/2 and ERK2 targeting drugs. Indeed, clinical trails for the Afatinib and Selumetinib combinations are currently underway (https://clinicaltrials.gov/ct2/show/NCT02450656). There are several MYC-related modules identified by NETPHIX. An interesting example is the module for PHA-793887 ( Figure S2a ), comprising genes KIT, MYC, and NRAS (phenotype permutation p ph ≤ 10 −2 ; network permutation p net ≤ 10 −2 ), all known cancer genes. PHA-793887 targets the cell cycle through the inhibition of members of the cyclin dependent kinase (CDK) family, including CDK2. KIT, MYC, and NRAS are all related to the PI3K-AKT signaling pathway (involved in cell cycle progression) that is upstream of CDK2. Another notable MYC-related module reported by NET-PHIX comprises CDKN1B, EGFR, and MYC and is associated (phenotype permutation p ph ≤ 10 −2 ; network permutation p net ≤ 4 × 10 −2 ) with increased sensitivity to Pelitinib ( Figure S2b ). Pelitinib targets epidermal growth factor receptor (EGFR) and all three genes in the module are related to the ErbB signaling pathway: EGFR is a member of the pathway, while both CDKN1B and MYC are downstream of the pathway ( Figure S2b) . In summary,the modules identified by NETPHIX are in good correspondence with the action of the respective drugs, suggesting that NETPHIX can correctly identify relevant modules and the modules can thus be used to predict potential patient-specific drug combinations and to provide guidance to personalized treatment.
Materials and method details 4.1 Datasets
Drug sensitivity dataset: The Genomics of Drug Sensitivity in Cancer Project( https://www. cancerrxgene.org/) consists of drug sensitivity data generated from high-throughput screening using fluorescence-based cell viability assays following 72 hours of drug treatment. In particular, we considered the area under the curve for each experiment as a phenotype. These scores are provided in the file portal-GDSC AUC-201806-21.txt available through the DepMap data portal (https://depmap.org) for 265 compounds and 743 cell lines, with 736 having alteration data available through the DepMap portal. For the DepMap experiments [26, 27] , we used the alteration provided at https://depmap.org/portal/download/all/. We downloaded the data on July 6
th 2018. In particular we used mutation data from the file portal-mutation-2018-06-21.csv that includes binary entries for 18,652 gene-level mutations. Additionally we considered 22,746 amplifications and 22,746 deletions computed from the gene copy number data in portal-copy number relative-2018-06-21.csv, with an amplification defined by a copy number above 2 and a deletion defined by a copy number below -1.
Interaction network For functional interactions among genes, we used the data downloaded from STRING database version 10.0 (https://string-db.org). We only included the edges with high confidence scores (≥ 900) as an input toṪhe resulting interaction network includes 9,215 nodes and 160,249 edges.
Preprocessing drug sensitivity data: For every drug response profile, we excluded samples with missing values for that phenotype, which results in a different number of samples for each phenotype. The number of samples varied between 240 and 705. To generate drug sensitivity values for the patients, we took the negatives of cell viability (i.e., increased cell survival indicates decreased sensitivity to the drug and vice versa) and then normalized the phenotype values before running the algorithm, by using standard z-scores (subtracting the average value j∈J w j /m from each weight w j and dividing the result by the standard deviation of the (original) w j 's), in order to have both positive and negative phenotype values. Following previously established practice [16] , we discarded features with low or high frequency, that correspond to noisy features and to features whose frequency is too high to show a significant association with drug response in combination with other features, respectively. In particular, features present in less than 1% samples or more than 25% samples were excluded from our analyses.
Generating simulated data: For the background of simulation data, we use the same gene alteration table and interactions from drug sensitivity dataset described previously in this section. The phenotype values for individual samples are randomly drawn from normal distribution N (0, 1). We then planted randomly generated phenotypes and associated modules to the background as follows. Phenotypes: α fraction of patients P (α) (α = 0.1, 0.2, and 0.3) were randomly selected and assigned phenotype values drawn randomly from N (z, 0.5) where z is a z-score corresponding to a cumulative p-value p (p = 0.005, 0.1, 0.99, and 0.995). Associated gene modules: we randomly selected a gene set S(k) of size k (k = 3, 4, and 5) and added random alterations in S(k) for patients P (α) so that each patient in P (α) has an alteration in exactly one gene in S(k). Therefore, the added alterations among the patients P (α) are mutually exclusive although there may be overlapping mutations due to the background alterations. We also added random edges among the genes S(k) so that they satisfy the density constraints. We generated 10 random instances for each combination of parameters (k, α, z) and ran the module identification algorithms.
Method details
Selecting module size k: To identify significant modules for each of 530 instances of drug response data (increase or decreased sensitivity of each drug experiment), we ran NETPHIX with different k's and choose the best k for each instance as follows: start with k = 1 and increase k by one until the improvement is not sufficient (up to k = 5). We chose 5% improvement cutoff over the previous k for stop condition ((OPT(k+1)-OPT(k))/OPT(k) < 0.05). Our simulation results show that the improvement of the optimal objective value decreases significantly once the algorithm reaches the size of a correct solution (Fig. S3a) . In addition, the algorithm performs phenotype permutation test and stops if p-values starts increasing (i.e., less significant than the previous run). Once the algorithm stops, we define the identified module to be significant if the FDR adjusted p-value (Benjamini/Hochberg) is less than 0.1.
Phenotype permutation test:
In the phenotype permutation, the dependencies among alterations in genes are maintained, while the association between alterations and the phenotype is removed. In particular, a permuted dataset under the null distribution is obtained as follows: the graph G = (V, E) and the sets P i , i ∈ V are the same as observed in the data; the values of the phenotype are randomly permuted across the samples. To estimate the p-value for the solutions obtained by our methods we used the following standard procedure: 1) we run an algorithm on the real data D, obtaining a solution with objective function o D ; 2) we generate N permuted datasets as described above; 3) we run the same algorithm on each permuted dataset; 4) the p-value is then given by (e + 1)/(N + 1), where e is the number of permuted datasets in which our algorithm found a solution with objective function ≥ o D .
Network permutation test:
In the second permutation test, a permuted dataset under the null distribution is obtained by generating permuted networks (swapping edges to preserve the degree of nodes) while maintaining the same phenotype profile and gene alteration table. To generate each permuted network, we performed edge swapping 100 * |E| times. This permutation measures how likely a random network would have a module with the objective value at least the optimal. The test statistics used to compute p-values is again the value of the objective function of the solution and the p-value is calculated with same procedure described above for phenotype permutation test.
Robustness test:
To test the robustness of gene selection in modules, we use the bootstrapping method. More specifically, we sampled patients with replacement to generate random instances of the same number of samples. Let B i be a random set of patients generated with bootstrapping in the i-th iteration. The phenotype and alteration profiles of the patients B i were used as inputs to and the optimal solution O i was computed with the random instances. We repeated bootstrapping 100 times to obtain { B 1 , B 2 , ... B 100 }, for which optimal solutions { O 1 , O 2 , ... O 100 } were computed, respectively. The robustness of a gene (or an edge, resp.) in the optimal solution is obtained by counting the number of time the gene (pair of genes, resp.) appears in { O 1 , O 2 , ... O 100 }.
Conclusions
We developed a new computational method, NETPHIX (NETwork-to-PHenotpe mapping LeveragIng eXlusivity), for the identification of mutated subnetworks that are associated with a continuous phenotype. Using simulations and analyzing experimental data, we showed that NETPHIX can uncover the subnetworks associated with response to cancer drugs with high precision. Using NETPHIX to study drug response in cancer, we found many statistically significant and biologically relevant modules including two distinct MAPK/ERK signaling related modules associated with opposite response to drugs targeting MEK1/2 and ERK2 genes. We also demonstrated that subnetworks identified by NETPHIX can suggest combination drug therapy and guide personalized medicine. The applicability of NETPHIX can go far beyond the drug response discussed in this paper, to any continuous cancer phenotypes. We expect that NETPHIX will find broad applications in many types of network-to-phenotype association studies.
Supplementary Materials S1 Algorithm for Sparse networks
The approach described in the main text works well for dense networks, see Section 2 for results on cancer data. For sparse networks imposing high density for the selected subnetwork might not be the best approach. Therefore we also propose a variation of the formulation presented in section 2.2 to handle sparse networks. Given a graph G = (V, E) and two distinct nodes h and l from V , a subset of nodes N ⊆ V \{h, l} is an (h, l) node separator if and only if after removing N from V there is no path between h and l in G. Let N (h, l) denote the family of all (h, l) node separators. A separator N ∈ N (h, l) is minimal if N \{i} is not an (h, l) separator for any i ∈ N . As an alternative to constraint (6) in the formulation above one could impose the following connectivity constraint:
Constraint (8) 
